A method for evaluating a compound to determine the relative or absolute therapeutic capability of a compound to pharmacologically inhibit ischemia induced activation of iPLA2β in an intact myocardium which comprises treating intact myocardium with a compound, inducing ischemia in the myocardium tissue and determining if there has been a change in expression of iPLA2β, its activity or in the iPLA2β regulating network and determining if there has been a change then that the compound is an anti-arrhythmia or myocardial salvage drug.
展开▼
